Potential remdesivir-related transient bradycardia in patients with coronavirus disease 2019 (COVID-19).
作者信息
Pallotto Carlo, Suardi Lorenzo R, Gabbuti Andrea, Esperti Sara, Mecocci Lorenzo, Blanc Pierluigi
机构信息
Infectious Diseases Unit 1, Santa Maria Annunziata Hospital, Azienda USL Toscana Centro, Florence, Italy.
Section of Infectious Diseases, Department of Medicine, University of Perugia, Perugia, Italy.
出版信息
J Med Virol. 2021 May;93(5):2631-2634. doi: 10.1002/jmv.26898. Epub 2021 Mar 3.
Abstract
摘要
相似文献
1
Potential remdesivir-related transient bradycardia in patients with coronavirus disease 2019 (COVID-19).2019冠状病毒病（COVID-19）患者中与瑞德西韦相关的潜在短暂性心动过缓
J Med Virol. 2021 May;93(5):2631-2634. doi: 10.1002/jmv.26898. Epub 2021 Mar 3.
2
Remdesivir-Induced Bradycardia in COVID-19: A Single Center Prospective Study.瑞德西韦致新型冠状病毒肺炎患者心动过缓：一项单中心前瞻性研究
Circ Arrhythm Electrophysiol. 2021 Jul;14(7):e009811. doi: 10.1161/CIRCEP.121.009811. Epub 2021 Jun 29.
3
Assessment of adverse events associated with remdesivir use for coronavirus disease 2019 using real-world data.使用真实世界数据评估瑞德西韦治疗 2019 冠状病毒病相关不良反应。
Expert Opin Drug Saf. 2021 Dec;20(12):1559-1564. doi: 10.1080/14740338.2021.1962846. Epub 2021 Aug 5.
4
Compassionate use of remdesivir for treatment of severe coronavirus disease 2019 in pregnant women at a United States academic center.在美国一家学术中心对瑞德西韦同情用药治疗妊娠合并重症2019冠状病毒病的研究。
Am J Obstet Gynecol MFM. 2020 Aug;2(3):100164. doi: 10.1016/j.ajogmf.2020.100164. Epub 2020 Jun 25.
5
Remdesivir as a broad-spectrum antiviral drug against COVID-19.瑞德西韦作为一种广谱抗 COVID-19 病毒药物。
Eur Rev Med Pharmacol Sci. 2021 Jan;25(1):541-548. doi: 10.26355/eurrev_202101_24426.
6
Should Remdesivir Be Used for the Treatment of Patients With COVID-19? Rapid, Living Practice Points From the American College of Physicians (Version 1).瑞德西韦是否应用于治疗 COVID-19 患者？美国医师学会的快速实践要点（第 1 版）。
Ann Intern Med. 2021 Feb;174(2):229-236. doi: 10.7326/M20-5831. Epub 2020 Oct 5.
7
Evaluation of the efficacy and safety of intravenous remdesivir in adult patients with severe COVID-19: study protocol for a phase 3 randomized, double-blind, placebo-controlled, multicentre trial.评估静脉用瑞德西韦治疗成人重症 COVID-19 的疗效和安全性：一项 3 期随机、双盲、安慰剂对照、多中心试验的研究方案。
Trials. 2020 May 24;21(1):422. doi: 10.1186/s13063-020-04352-9.
8
Safety and effectiveness of remdesivir in hospitalized patients with COVID-19 and severe renal impairment: experience at a large medical center.瑞德西韦在 COVID-19 住院患者和严重肾功能损害患者中的安全性和有效性：一家大型医疗中心的经验。
Ann Med. 2024 Dec;56(1):2361843. doi: 10.1080/07853890.2024.2361843. Epub 2024 Jun 3.
9
Liver injury in remdesivir-treated COVID-19 patients.接受瑞德西韦治疗的新冠肺炎患者的肝损伤
Hepatol Int. 2020 Sep;14(5):881-883. doi: 10.1007/s12072-020-10077-3. Epub 2020 Jul 28.
10
Bradycardia associated with remdesivir therapy for COVID-19 in a 59-year-old man.一名59岁男性在接受瑞德西韦治疗新型冠状病毒肺炎时出现心动过缓。
CMAJ. 2021 Apr 26;193(17):E612-E615. doi: 10.1503/cmaj.210300.
引用本文的文献
1
Incidence of bradycardia with the use of remdesivir for coronavirus disease of 2019 and risk factor analysis.使用瑞德西韦治疗2019冠状病毒病时心动过缓的发生率及危险因素分析。
Int J Crit Illn Inj Sci. 2024 Oct-Dec;14(4):203-207. doi: 10.4103/ijciis.ijciis_57_24. Epub 2024 Dec 23.
2
Remdesivir-Induced Bradycardia and Mortality in SARS-CoV-2 Infection, Potential Risk Factors Assessment: A Systematic Review and Meta-Analysis.瑞德西韦在新冠病毒感染中导致的心动过缓和死亡率：潜在风险因素评估——一项系统评价与荟萃分析
J Clin Med. 2023 Dec 5;12(24):7518. doi: 10.3390/jcm12247518.
3
Remdesivir-associated bradycardia in COVID-19: a rapid review protocol.瑞德西韦相关 COVID-19 患者的心动过缓：快速综述方案。
BMJ Open. 2023 May 31;13(5):e068564. doi: 10.1136/bmjopen-2022-068564.
4
Identification of Bradycardia Following Remdesivir Administration Through the US Food and Drug Administration American College of Medical Toxicology COVID-19 Toxic Pharmacovigilance Project.通过美国食品和药物管理局美国医学毒理学学院 COVID-19 毒理学药物警戒项目鉴定瑞德西韦给药后的心动过缓。
JAMA Netw Open. 2023 Feb 1;6(2):e2255815. doi: 10.1001/jamanetworkopen.2022.55815.
5
Remdesivir associated sinus bradycardia in patients with COVID-19: A prospective longitudinal study.瑞德西韦与新型冠状病毒肺炎患者窦性心动过缓的相关性：一项前瞻性纵向研究。
Front Pharmacol. 2023 Jan 17;13:1107198. doi: 10.3389/fphar.2022.1107198. eCollection 2022.
6
Remdesivir-induced Bradycardia is not Associated with Worse Outcome in Patients with COVID-19: A Retrospective Analysis.瑞德西韦引起的心动过缓与 COVID-19 患者的不良结局无关：一项回顾性分析。
Am J Cardiovasc Drugs. 2022 Nov;22(6):705-710. doi: 10.1007/s40256-022-00547-4. Epub 2022 Aug 25.
7
Clinical Characteristics and Implications of Bradycardia in COVID-19 Patients Treated with Remdesivir: A Single-Center Retrospective Cohort Study.瑞德西韦治疗的 COVID-19 患者心动过缓的临床特征及意义：一项单中心回顾性队列研究。
Clin Drug Investig. 2022 Sep;42(9):763-774. doi: 10.1007/s40261-022-01187-x. Epub 2022 Aug 17.
8
Bradyarrhythmia After Remdesivir Administration in SARS-CoV-2: A Review of Literature and Meta-Analysis of Observational Studies in Epidemiology.瑞德西韦治疗新型冠状病毒肺炎后的缓慢性心律失常：文献综述及流行病学观察性研究的荟萃分析
Cardiol Res. 2022 Jun;13(3):135-143. doi: 10.14740/cr1377. Epub 2022 May 10.
9
The potential of remdesivir to affect function, metabolism and proliferation of cardiac and kidney cells in vitro.瑞德西韦在体外影响心脏和肾脏细胞功能、代谢和增殖的潜力。
Arch Toxicol. 2022 Aug;96(8):2341-2360. doi: 10.1007/s00204-022-03306-1. Epub 2022 May 17.
10
Prognostic Value of 12-Leads Electrocardiogram at Emergency Department in Hospitalized Patients with Coronavirus Disease-19.12导联心电图对新型冠状病毒肺炎住院患者在急诊科的预后价值
J Clin Med. 2022 Apr 30;11(9):2537. doi: 10.3390/jcm11092537.
本文引用的文献
1
Potential Therapeutic Options for COVID-19: Current Status, Challenges, and Future Perspectives.2019冠状病毒病的潜在治疗选择：现状、挑战及未来展望
Front Pharmacol. 2020 Sep 15;11:572870. doi: 10.3389/fphar.2020.572870. eCollection 2020.
2
Diagnostic approaches and potential therapeutic options for coronavirus disease 2019.2019年冠状病毒病的诊断方法和潜在治疗选择。
New Microbes New Infect. 2020 Nov;38:100770. doi: 10.1016/j.nmni.2020.100770. Epub 2020 Sep 30.
3
Quality of adverse event reporting in clinical trials of remdesivir in patients with COVID-19.瑞德西韦用于新冠肺炎患者临床试验中不良事件报告的质量
Eur J Clin Pharmacol. 2021 Mar;77(3):435-437. doi: 10.1007/s00228-020-03008-6. Epub 2020 Oct 4.
4
Risk factors for non-invasive/invasive ventilatory support in patients with COVID-19 pneumonia: A retrospective study within a multidisciplinary approach.COVID-19 肺炎患者接受无创/有创通气支持的风险因素：多学科方法的回顾性研究。
Int J Infect Dis. 2020 Nov;100:258-263. doi: 10.1016/j.ijid.2020.09.012. Epub 2020 Sep 11.
5
Effectiveness of remdesivir in patients with COVID-19 under mechanical ventilation in an Italian ICU.雷米迪维在意大利 ICU 机械通气 COVID-19 患者中的疗效。
J Antimicrob Chemother. 2020 Nov 1;75(11):3359-3365. doi: 10.1093/jac/dkaa321.
6
Increased CD4/CD8 ratio as a risk factor for critical illness in coronavirus disease 2019 (COVID-19): a retrospective multicentre study.2019冠状病毒病（COVID-19）中CD4/CD8比值升高作为危重症风险因素的回顾性多中心研究
Infect Dis (Lond). 2020 Sep;52(9):675-677. doi: 10.1080/23744235.2020.1778178. Epub 2020 Jun 16.
7
Remdesivir for the Treatment of Covid-19 - Final Report.瑞德西韦治疗 COVID-19 的疗效 - 最终报告。
N Engl J Med. 2020 Nov 5;383(19):1813-1826. doi: 10.1056/NEJMoa2007764. Epub 2020 Oct 8.
Zotero 插件